Senores Pharma profit surges 56% in Q1FY27; eyes ₹3,000 cr revenue
Senores Pharmaceuticals reported a 56% YoY rise in net profit to ₹31 crore for Q1FY27, driven by 42% growth in regulated markets. Management reaffirmed its long-term target of ₹2,500-3,000 crore revenue within three to four years.
*this image is generated using AI for illustrative purposes only.
Senores Pharmaceuticals reported a consolidated net profit of ₹31 crore for the quarter ended June 30, 2026 (Q1FY27), marking a 56% year-on-year increase. The strong performance was driven by a 42% surge in revenue from its Regulated Markets segment and steady expansion in Emerging Markets, positioning the company to achieve its long-term revenue target of ₹2,500 crore to ₹3,000 crore within three to four years.
The Board of Directors approved the unaudited financial results on July 27, 2026, pursuant to Regulation 33 and Regulation 47(1)(b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by statutory auditors Pankaj R. Shah and Associates. A transcript of the earnings conference call held on July 27, 2026, was filed with stock exchanges on August 3, 2026, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.
Financial Performance
Consolidated revenue from operations rose 36% to ₹180.21 crore from ₹132.56 crore in Q1FY26. Consolidated EBITDA stood at ₹54 crore, reflecting an 87% year-on-year growth and an expansion of approximately 800 basis points in margins. Profit before tax was ₹39.46 crore, compared to ₹26.49 crore in the prior year quarter. Other income declined to ₹2.81 crore from ₹8.79 crore due to lower one-time gains, though operational profitability remained robust.
| Metric | Q1FY27 (₹ Cr) | Q1FY26 (₹ Cr) | YoY Change |
|---|---|---|---|
| Revenue From Operations | 180.21 | 132.56 | +36% |
| EBITDA | 54.00 | 28.88* | +87% |
| Net Profit After Tax | 31.00 | 19.87** | +56% |
| Earnings Per Share (Basic) | ₹6.61 | ₹4.60 | +44% |
*Note: EBITDA for Q1FY26 derived from disclosed growth rate and current EBITDA. **Note: Prior year PAT derived from disclosed growth rate and current PAT.
On a standalone basis, the parent company reported a net profit of ₹1.03 crore, down from ₹2.70 crore in Q1FY26. Standalone revenue from operations was ₹26.99 crore, up from ₹16.13 crore in the previous year. This divergence highlights the significant contribution of subsidiaries, particularly in international markets.
Segmental Highlights
The Regulated Markets business, comprising the US and Canada, remained the primary growth driver with revenue reaching ₹127.8 crore, up 42% from ₹90.1 crore in Q1FY26. This segment contributed 71% of total revenue with an EBITDA margin of approximately 40%. The Emerging Markets segment also showed steady growth, with revenue rising 30% to ₹37.6 crore from ₹29.0 crore, contributing 21% of total revenue at an EBITDA margin of approximately 14%. Branded Generics revenue contracted slightly by 2.4% to ₹8.0 crore.
Swapnil Shah, Managing Director, attributed the performance to the expansion of the product portfolio, which has nearly doubled from 30 ANDAs as of June 2025 to 58 approved ANDAs as of June 2026, of which 23 have been commercialized. The CDMO/CMO business saw its commercialized products grow from 27 to 34, while pipeline products increased from 15 to 16.
Management Guidance
Management expects FY27 revenue growth of approximately 30% to 40% and PAT growth of about 50% to 60%, with a similar trajectory expected thereafter. Planned CapEx for FY27 is approximately ₹130 crore, primarily directed towards increasing oral solid capacity and starting a pilot injectable plant, with a run rate of ₹60 crore to ₹75 crore guided for the following year.
| Guidance Parameter | Details |
|---|---|
| FY27 Revenue Growth | ~30% to 40% |
| FY27 PAT Growth | ~50% to 60% |
| Planned FY27 CapEx | ~₹130 crore |
| Long-Term Revenue Target | ₹2,500 crore to ₹3,000 crore (3–4 years) |
| Emerging Markets FY27 EBITDA Margin | 18% to 20% |
| Branded Generics YoY Growth Target | 30% to 40% |
For the Emerging Markets business, management guided full-year FY27 EBITDA margins of 18% to 20%, despite a sequential dip to 14% in Q1FY27 from 20% in Q4FY26. The Branded Generics segment is expected to achieve 30% to 40% year-over-year growth, targeting EBITDA margins of 35% to 40% over sales volume.
IPO Fund Utilization
As of June 30, 2026, Senores Pharmaceuticals had utilized ₹399.5 crore out of the ₹500 crore raised through its IPO, with the unutilized amount standing at ₹100.5 crore. Key utilization areas included repayment of borrowings (₹73.1 crore, fully utilized), investment in subsidiary Havix for borrowing repayment (₹20.2 crore, fully utilized), working capital requirements (₹43.26 crore utilized against ₹43.3 crore proposed), inorganic growth and strategic initiatives (₹161.63 crore utilized against ₹161.9 crore proposed), and offer expenses (₹34.8 crore utilized against ₹35.0 crore proposed). Only ₹6.98 crore was utilized towards the investment in Havix for setting up a manufacturing facility for sterile injections in Atlanta, leaving ₹100.0 crore unutilized for this specific purpose.
What the Numbers Show
The significant disparity between standalone and consolidated profitability indicates that Senores Pharmaceuticals' value creation is increasingly dependent on its international subsidiaries. While the Indian entity reported modest standalone profits of ₹1.03 crore, the group delivered ₹31 crore in net profit, driven largely by the high-margin Regulated Markets segment. The sharp decline in other income did not dampen overall profit growth, suggesting that core operational efficiency improvements—evidenced by the 800-basis-point margin expansion—are sustainable drivers rather than one-off financial gains.
Historical Stock Returns for Senores Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.42% | +1.40% | +9.26% | +85.66% | +116.34% | +171.66% |
How will the ₹130 crore CapEx for the new injectable pilot plant impact near-term cash flows and debt levels before the facility becomes revenue-generating?
What specific regulatory or competitive risks could hinder the commercialization of the 35 approved but yet-to-launch ANDAs in the US market?
Can Senores Pharmaceuticals sustain the guided 18-20% EBITDA margin in Emerging Markets despite recent sequential dips and intense local competition?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
